

B1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68108 A1

(51) International Patent Classification⁷: **A61K 35/12**,
38/28, C12Q 1/00, C12N 5/08, 5/10

(21) International Application Number: PCT/US01/07628

(22) International Filing Date: 9 March 2001 (09.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/522,376 10 March 2000 (10.03.2000) US

(71) Applicant (for all designated States except US): **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; Office of Technology Transfer, 1111 Franklin Street, Fifth Floor, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEVINE, Fred** [US/US]; 2427 Malibu Way, Del Mar, CA 92014 (US). **DUFAYET, Dominique** [FR/US]; 5210 Fiore Terrace, Villa Renaissance L311, San Diego, CA 92122 (US).

(74) Agents: **PARENT, Annette, S.** et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INDUCTION OF BETA CELL DIFFERENTIATION IN HUMAN CELLS BY STIMULATION OF THE GLP-1 RECEPTOR

(57) Abstract: The present invention provides methods for inducing insulin gene expression in cultured pancreas cells, the method comprising contacting a culture of endocrine pancreas cells expressing a PDX-1 gene with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions such that the cells are in contact with other cells in the culture, thereby inducing insulin gene expression in the cells. The invention also provides high throughput screening methods for modulators of B-cell function, stable cultures of cells made by the methods of the invention, and methods of treating a human subject using the methods of the invention.

WO 01/68108 A1

INDUCTION OF BETA CELL DIFFERENTIATION IN HUMAN CELLS BY STIMULATION OF THE GLP-1 RECEPTOR

CROSS-REFERENCES TO RELATED APPLICATIONS

5 The present application claims priority to USSN 09/522,376, filed March 10, 2000, herein incorporated by reference in its entirety.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

10 This invention was made with Government support under Grant No. 5 R01 DKK55283-02 and 5 R01 DK55065-02, awarded by the National Institutes of Health. The Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

15 Transplantation of cells exhibiting glucose-responsive insulin secretion has the potential to cure diabetes. However, this approach is limited by an inadequate supply of cells with that property, which is exhibited only by pancreatic β -cells. The development of expanded populations of human β -cells that can be used for cell transplantation is therefore a major goal of diabetes research (D. R. W. Group, "Conquering diabetes: a strategic plan for the 21st century" *NIH Publication No. 99-4398* (National Institutes of Health, 1999)). A number of alternative approaches are being pursued to achieve that goal, including using porcine tissue as a xenograft (Groth *et al.*, *J Mol Med* 77:153-4 (1999)), expansion of primary human β -cells with growth factors and extracellular matrix (Beattie *et al.*, *Diabetes* 48:1013-9 (1999)), and generation of immortalized cell lines that exhibit glucose-responsive insulin secretion (Levine, *Diabetes/Metabolism Reviews* 1: 209-46 (1997)).

25 Although there has been great interest in using porcine islets, they are difficult to manipulate *in vitro* and concerns have been raised about endogenous and exogenous xenobiotic viruses being transmitted to graft recipients (Weiss, *Nature* 30 391:327-8 (1998)). With primary human β -cells, entry into the cell cycle can be achieved using hepatocyte growth factor/scatter factor ("HGF/SF") plus extracellular matrix ("ECM") (Beattie *et al.*, *Diabetes* 48:1013-9 (1999), Hayek *et al.*, *Diabetes* 44:1458-1460 (1995)). However, this combination, while resulting in a $2-3 \times 10^4$ -fold expansion in the

number of cells, is limited by cellular senescence and loss of differentiated function, particularly pancreatic hormone expression (Beattie *et al.*, *Diabetes* 48:1013-9 (1999)).

Immortalized cell lines from the human endocrine pancreas have been created to develop β -cell lines that exhibit glucose responsive insulin secretion (Wang *et al.*, *Cell Transplantation* 6:59-67 (1997), Wang *et al.*, *Transplantation Proceedings* 29:2219 (1997), Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999)). The cell lines are made by infecting primary cultures of cells from various sources including adult islets, fetal islets, and purified β -cells, with viral vectors expressing the potent dominant oncogenes such as SV40 T antigen and H-ras^{val12} (Wang *et al.*, *Cell Transplantation* 6:59-67 (1997), Wang *et al.*, *Transplantation Proceedings* 29:2219 (1997), Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999); see also U.S. Patent No. 5,723,333). The combined effect of those oncogenes is to trigger growth factor-independent and extracellular matrix (ECM)-independent entry into the cell cycle, as well as to prolong the lifespan of the cells from 10-15 population doublings or primary cells to approximately 150 doubling for the oncogene-expressing cells (Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999)). Further introduction of the gene encoding the hTERT component of telomerase results in immortalization, allowing the cells to be grown indefinitely (Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999)).

Although the cell lines grow indefinitely, they lose differentiated function, similar to growth-stimulated primary β -cells. Methods of stimulating differentiation of the cell lines into insulin-secreting β -cells are therefore desired. Such cells could then be transplanted *in vivo* as a treatment for diabetes.

SUMMARY OF THE INVENTION

Induction of β -cell differentiation in cultured human β -cells was achieved by stimulating multiple signaling pathways, including those downstream of the homeodomain transcription factor PDX-1, cell-cell contact, and the glucagon-like peptide-1 (GLP-1) receptor. Synergistic activation of those pathways resulted in differentiation of the cultured human β -cells, which initially express no detectable pancreatic hormones, into fully functional β -cells that exhibit glucose-responsive insulin secretion. Furthermore, these cells can be transplanted *in vivo* and demonstrate glucose-responsive expression of insulin. The ability to grow unlimited quantities of functional

human β -cells *in vitro* provides the means for a definitive cell transplantation therapy for treatment of diabetes.

In one aspect, the present invention provides a method for inducing insulin gene expression in cultured endocrine pancreas cells, the method comprising the steps of
5 (i) expressing a PDX-1 gene in cells that have been cultured under conditions such that the cells are in contact with other cells in the culture; and (ii) contacting the cells with a GLP-1 receptor agonist, thereby inducing insulin gene expression in the cells.

In another aspect, the present invention provides a method of identifying a compound that modulates β -cell function, the method comprising the steps of contacting
10 cells made by the method described above with the compound and determining the effect of the compound on β -cell function.

In another aspect, the present invention provides a stable culture of endocrine pancreas cells, wherein the cells are in contact with other cells in the culture, wherein the cells express a PDX-1 gene, and wherein insulin gene expression is
15 stimulated in the cells when exposed to an effective amount of a GLP-1 receptor agonist.

In another aspect, the present invention provides a method of treating a diabetic subject by providing to the subject cells that secrete insulin in response to glucose, the method comprising the steps of: (i) contacting a culture of endocrine pancreas cells expressing a PDX gene with a GLP-1 receptor agonist, wherein the cells
20 have been cultured under conditions such that the cells are in contact with other cells in the culture; and (ii) administering the cells to the subject, thereby providing to the subject cells that secrete insulin in response to glucose.

In one embodiment, the GLP-1 receptor agonist is a GLP-1 analog or has an amino acid sequence of a naturally occurring peptide. In another embodiment, the
25 GLP-1 receptor agonist is GLP-1, exendin-3, or exendin-4.

In one embodiment, the cells are cultured as aggregates in suspension.

In one embodiment, the PDX-1 gene is endogenous to the cells. In another embodiment, the PDX-1 gene is recombinant.

In one embodiment, the cells are human cells. In another embodiment, the
30 cells are β lox5 cells.

In one embodiment, the cells express a recombinant oncogene. In another embodiment, the cells express a recombinant oncogene. In another embodiment, the cells

express a recombinant oncogene. In another embodiment, the cells express a recombinant telomerase gene.

In one embodiment, the diabetic subject is a human. In another embodiment, the subject has Type I insulin dependent diabetes.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Flow cytometric analysis of FAD autofluorescence in a single cell suspension of human islets used to develop the β lox5 cell line.

Figure 2: RT-PCR analysis of pancreatic hormone gene expression in β lox5. The conditions tested were β lox5 cells grown in monolayer culture, β lox5 cells infected with a retroviral vector expressing PDX-1, β lox5 cells grown as three-dimensional aggregates, and β lox5 cells treated with exendin-4. Fig. 2(A) insulin; Fig. 2(B) quantitative RT-PCR analysis of insulin gene expression; Fig. 2(C) other pancreatic hormones. Aggregation of cells into three-dimensional clusters and the retroviral vector expressing PDX-1 have been described previously (Itkin-Ansari *et al.*, submitted). Exendin-4 (Sigma) was used at a concentration of 10 nM. RT-PCR for insulin, somatostatin, glucagon, and IAPP have been described previously (Itkin-Ansari *et al.*, submitted). Quantitative RT-PCR was done by interpolation from a standard curve constructed using a plasmid containing the human insulin cDNA.

Figure 3: Analysis of transcription factors expressed in β lox5 cells. Fig. 3(A) electrophoretic mobility shift assay (EMSA) of PDX-1. EMSA for PDX-1 was performed using a probe derived from the human insulin promoter A5 element. Figs. 3(B&C) RT-PCR analysis of BETA2 and Pax6. Fig. 3(D) Western blot analysis of CREB. Fig. 3(E) EMSA of RIPE3b.

Figure 4. Insulin protein in induced β lox5 cells. Fig. 4(A) Insulin immunohistochemistry; Fig. 4(B) Insulin western blot analysis of conditioned medium.

Figure 5. Analysis of glucose-responsive insulin secretion. Fig. 5(A) RT-PCR for glucokinase. Fig. 5(B) Radioimmunoassay for insulin secreted from induced β lox5 cells grown in culture medium containing increasing concentrations of glucose. Induced β lox5 cells were cultured in DME containing a single concentration of added glucose for one hour. Medium was harvested and assayed for insulin by RIA.

Figure 6. RIA of c-peptide in nude mice transplanted with induced β lox5 cells.

DETAILED DESCRIPTION OF THE INVENTION

INTRODUCTION

Beginning with a cell line that exhibited few β -cell characteristics, despite
5 having been originally derived from human β -cells, complete β -cell function has been
successfully induced *in vitro*. In addition, these cells have been transplanted into mice and
are shown to produce insulin in a glucose responsive manner. Induction of β -cell
differentiation in cells such as β lox5 cells requires three inducing factors, PDX-1, cell-
cell contact, and GLP-1 receptor agonists such as exendin-4. Cultured cell lines such as
10 TRM-6 (δ -cell lineage) and β lox5 (β -cell lineage) are powerful tools that should allow
identification of the full complement of genes that are required for endocrine cell
development and function. Furthermore, the requirement for multiple interacting
inducing factors provides an opportunity to study how different signal transduction
pathways interact with one another to control a complex differentiation program.

15 The availability of an unlimited source of functional human β -cells has
important implications for diabetes. One straightforward application is in exploring
aspects of β -cell biology that would benefit from an unlimited, homogeneous source of
cells. High-throughput screening for new diabetes drugs is one such application. The
cells of the invention can be used, e.g., to screen for small molecule or macromolecule
20 GLP-1 receptor agonists or other compounds that enhance insulin expression. In
addition, cells such as those described herein can be used in a cell transplantation therapy
for diabetes. Cells that express PDX-1 and are in cell-to-cell contact with other cells are
stimulated with a GLP-1 receptor agonist, as described herein. Such cells are then
transplanted into a suitable mammalian host, preferably a human. Such cells exhibit
25 glucose-responsive insulin secretion *in vivo*.

In one embodiment, cultured cells useful in the practice of the invention
express one or more oncogenes, such as SV40 T antigen and Hras^{val12}, which minimally
transform the cells but stimulate growth and bypass cellular senescence. Other suitable
oncogenes include, e.g., HPV E7, HPV E6, c-myc, and CDK4 (*see also* U.S. Patent No.
30 5,723,333). In addition, the cells can be transduced with an oncogene encoding
mammalian telomerase, such as hTERT, to facilitate immortalization. Suitable oncogenes
can be identified by those of skill in the art, and partial lists of oncogenes are provided in
Bishop *et al.*, *RNA Tumor Viruses*, vol. 1, pp. 1004-1005 (Weiss *et al.*, eds, 1984), and

Watson *et al.*, *Molecular Biology of the Gene* (4th ed. 1987). In some cases the oncogenes provide growth factor-independent and ECM-independent entry into the cell cycle. Often the oncogenes are dominant oncogenes. The cells can be analyzed for recombinant oncogene expression by analysis of oncogene RNA or protein expression. Integration of an oncogene into the genome can be confirmed, e.g., by Southern blot analysis. Often, the oncogenes are delivered to the cells using a viral vector, preferably a retroviral vector, although any suitable expression vector can be used to transduce the cells (*see, e.g.*, U.S. Patent No. 5,723,333, which describes construction of vectors encoding one or more oncogenes and transduction of pancreas endocrine cells, *see also Halvorsen et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999)).

The vector used to create the cell lines incorporates recombinase sites, such as lox sites, so that the oncogenes can be deleted by expression of a recombinase, such as the cre recombinase, in the cells following expansion (Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999)). Deletion of the oncogenes is useful for cells that are to be transplanted in to a mammalian subject. Other recombinase systems include *Saccharomyces cerevisiae* FLP/FRT, lambda att/Int, R recombinase of *Zygosaccharomyces rouxii*. In addition, transposable elements and transposases could be used. Deletion of the oncogene can be confirmed, e.g., by analysis of oncogene RNA or protein expression, or by Southern blot analysis.

The cultured cells of the invention also express either endogenous or recombinant PDX-1 having PDX-1 activity, e.g., alleles, polymorphic variants, and orthologs (*see, e.g.*, Sander *et al.*, *J. Mol. Med.* 71:327-340 (1997)). Endogenous expression of PDX-1 can be induced using transcription factors such as hepatocyte nuclear factor 3 beta, which is involved in pancreatic β -cell expression of the PDX-1 gene (*see, e.g.*, Wu *et al.*, *Molecular and Cellular Biology* 17:6002-6013 (1997)). Recombinant PDX-1 is delivered to the cells using expression vectors, e.g., viral vectors such as retroviral vectors, as described above.

The vectors used to transduce the cells can be any suitable vector, including viral vectors such as retroviral vectors. Preferably, the vector is one that provides stable transformation of the cells, as opposed to transient transformation.

This invention relies on routine techniques in the field of recombinant genetics. Basic texts disclosing the general methods of use in this invention include Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (2nd ed. 1989); Kriegler,

Gene Transfer and Expression: A Laboratory Manual (1990); and *Current Protocols in Molecular Biology* (Ausubel *et al.*, eds., 1994)).

GLP-1 receptor agonists, which are administered to the cells of the invention, include naturally occurring peptides such as GLP-1, exendin-3, and exendin-4 (see, e.g., U.S. Patent No. 5,424,286; U.S. Patent No. 5,705,483, U.S. Patent No. 5,977,071; U.S. Patent No. 5,670,360; U.S. Patent No. 5,614,492), GLP-1 analogs (see, e.g., U.S. Patent No. 5,545,618 and U.S. Patent No. 5,981,488), and small molecule analogs. GLP-1 receptor agonists may be tested for activity as described in U.S. Patent No. 5,981,488. Cells are contacted with a GLP-1 receptor agonist in a time and amount effective to induce insulin mRNA expression, as described herein. Typically, the cells are contacted with the GLP-1 receptor agonists for a discrete time period, as the GLP-1 receptor agonist is believed to act as a switch for insulin gene expression. Continuous administration of the GLP-1 receptor agonist is therefore not required.

Immune rejection of grafted cells has previously been a major obstacle to successful islet transplantation. Any universal human donor cell will be recognized by the immune system as an allograft. However, recent advances in therapy for allograft rejection may make this less of a concern (see, e.g., Kenyon *et al.*, *Proc. Natl Acad. Sci. USA* 96:8132-7 (1999)). An advantage of using an immortalized cell line as a source of transplantable cells is that they can be engineered to exhibit desirable qualities, including avoidance or suppression of host immune responses.

CELL CULTURE

This invention relies upon routine techniques in the field of cell culture, and suitable methods can be determined by those of skill in the art using known methodology (see, e.g., Freshney *et al.*, *Culture of Animal Cells* (3rd ed. 1994)). In general, the cell culture environment includes consideration of such factors as the substrate for cell growth, cell density and cell contract, the gas phase, the medium, and temperature.

The cells of the invention are grown under conditions that provide for cell to cell contact. In a preferred embodiment, the cells are grown in suspension as three dimensional aggregates. Suspension cultures can be achieved by using, e.g., a flask with a magnetic stirrer or a large surface area paddle, or on a plate that has been coated to prevent the cells from adhering to the bottom of the dish. In a preferred embodiment, the

cells are grown in Costar dishes that have been coated with a hydrogel to prevent them from adhering to the bottom of the dish.

For the cells of the invention that are cultured under adherent conditions, plastic dishes, flasks, roller bottles, or microcarriers in suspension are used. Other
5 artificial substrates can be used such as glass and metals. The substrate is often treated by etching, or by coating with substances such as collagen, chondronectin, fibronectin, and laminin. The type of culture vessel depends on the culture conditions, e.g., multi-well plates, petri dishes, tissue culture tubes, flasks, roller bottles, and the like.

Cells are grown at optimal densities that are determined empirically based
10 on the cell type. For example, a typical cell density for β lox5 cultures varies from 1×10^3 to 1×10^7 cells per ml. Cells are passaged when the cell density is above optimal.

Cultured cells are normally grown in an incubator that provides a suitable temperature, e.g., the body temperature of the animal from which the cells were obtained, accounting for regional variations in temperature. Generally, 37°C is the
15 preferred temperature for cell culture. Most incubators are humidified to approximately atmospheric conditions.

Important constituents of the gas phase are oxygen and carbon dioxide. Typically, atmospheric oxygen tensions are used for cell cultures. Culture vessels are usually vented into the incubator atmosphere to allow gas exchange by using gas
20 permeable caps or by preventing sealing of the culture vessels. Carbon dioxide plays a role in pH stabilization, along with buffer in the cell media and is typically present at a concentration of 1-10% in the incubator. The preferred CO₂ concentration typically is 5%.

Defined cell media are available as packaged, premixed powders or
25 presterilized solutions. Examples of commonly used media include DME, RPMI 1640, DMEM, Iscove's complete media, or McCoy's Medium (*see, e.g.,* GibcoBRL/Life Technologies Catalogue and Reference Guide; Sigma Catalogue). Typically, low glucose DME or RPMI 1640 are used in the methods of the invention. Defined cell culture media are often supplemented with 5-20% serum, typically heat inactivated, e.g., human horse,
30 calf, and fetal bovine serum. Typically, 10% fetal bovine serum is used in the methods of the invention. The culture medium is usually buffered to maintain the cells at a pH preferably from 7.2-7.4. Other supplements to the media include, e.g., antibiotics, amino acids, sugars, and growth factors such as hepatocyte growth factor/scatter factor.

PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATION

Pharmaceutically acceptable carriers are determined in part by the particular composition being administered (e.g., cell), as well as by the particular method used to administer the composition. Accordingly, there are a wide variety of suitable formulations of pharmaceutical compositions of the present invention (*see, e.g.,* 5 *Remington's Pharmaceutical Sciences*, 17th ed., 1989).

Formulations suitable for parenteral administration, such as, for example, by intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain 10 antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by direct surgical transplantation under the kidney, intraportal administration, 15 intravenous infusion, or intraperitoneal infusion.

Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets. The dose administered to a patient, in the context of the present invention should be sufficient to effect a beneficial therapeutic response in the patient over time. The dose will be determined by the efficacy of the particular cells employed 20 and the condition of the patient, as well as the body weight or surface area of the patient to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or transduced cell type in a particular patient.

In determining the effective amount of the cells to be administered in the treatment or prophylaxis of conditions owing to diminished or aberrant insulin 25 expression, the physician evaluates cell toxicities, transplantation reactions, progression of the disease, and the production of anti-cell antibodies. For administration, cells of the present invention can be administered in amount effective to provide normalized glucose responsive-insulin production and normalized glucose levels to the subject, taking into 30 account the side-effects of the cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.

ASSAYS FOR MODULATORS OF B-CELL FUNCTION

A. Assays

Assays using the cultured cells of the invention can be used to test for inhibitors and activators of β -cell function, e.g., insulin production and/or glucose responsive insulin production. Such modulators are useful for treating various disorders involving glucose metabolism, such as diabetes and hypoglycemia. Treatment of dysfunctions include, e.g., diabetes mellitus (all types); hyperinsulinism caused by insulinoma, drug-related, e.g., sulfonylureas or excessive insulin, immune disease with insulin or insulin receptor antibodies, etc. (*see, e.g., Harrison's Internal Medicine* (14th ed. 1998)).

Modulation is tested using the cultures of the invention by measuring insulin gene expression, optionally with administration of glucose, e.g., analysis of insulin mRNA expression using northern blot, dot blot, PCR, oligonucleotide arrays, and the like; and analysis of insulin protein expression (preproinsulin, proinsulin, insulin, or c-peptide) using, e.g., western blots, radio immune assays, ELISAs, and the like. Downstream effects of insulin modulation can also be examined. Physical or chemical changes can be measured to determine the functional effect of the compound on β cell function. Samples or assays that are treated with a potential inhibitor or activator are compared to control samples without the test compound, to examine the extent of modulation.

B. Modulators

The compounds tested as modulators of β -cell function can be any small chemical compound, or a macromolecule, such as a protein, sugar, nucleic acid or lipid. Typically, test compounds will be small chemical molecules and peptides. Essentially any chemical compound can be used as a potential modulator or ligand in the assays of the invention, although most often compounds can be dissolved in aqueous or organic (especially DMSO-based) solutions are used. The assays are designed to screen large chemical libraries by automating the assay steps and providing compounds from any convenient source to assays, which are typically run in parallel (e.g., in microtiter formats on microtiter plates in robotic assays). It will be appreciated that there are many suppliers of chemical compounds, including Sigma (St. Louis, MO), Aldrich (St. Louis, MO), Sigma-Aldrich (St. Louis, MO), Fluka Chemika-Biochemica Analytika (Buchs Switzerland) and the like.

In one preferred embodiment, high throughput screening methods involve providing a combinatorial chemical or peptide library containing a large number of potential therapeutic compounds (potential modulator or ligand compounds). Such “combinatorial chemical libraries” or “ligand libraries” are then screened in one or more
5 assays, as described herein, to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional “lead compounds” or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical
10 compounds generated by either chemical synthesis or biological synthesis, by combining a number of chemical “building blocks” such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks (amino acids) in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical
15 compounds can be synthesized through such combinatorial mixing of chemical building blocks.

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (*see, e.g.*, U.S. Patent 5,010,175, Furka, *Int. J. Pept. Prot. Res.* 37:487-493 (1991) and Houghton *et al.*, *Nature* 354:84-88 (1991)). Other
20 chemistries for generating chemical diversity libraries can also be used. Such chemistries include, but are not limited to: peptoids (*e.g.*, PCT Publication No. WO 91/19735), encoded peptides (*e.g.*, PCT Publication No. WO 93/20242), random bio-oligomers (*e.g.*, PCT Publication No. WO 92/00091), benzodiazepines (*e.g.*, U.S. Pat. No. 5,288,514),
25 diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs *et al.*, *Proc. Nat. Acad. Sci. USA* 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara *et al.*, *J. Amer. Chem. Soc.* 114:6568 (1992)), nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann *et al.*, *J. Amer. Chem. Soc.* 114:9217-9218 (1992)), analogous organic
30 syntheses of small compound libraries (Chen *et al.*, *J. Amer. Chem. Soc.* 116:2661 (1994)), oligocarbamates (Cho *et al.*, *Science* 261:1303 (1993)), and/or peptidyl phosphonates (Campbell *et al.*, *J. Org. Chem.* 59:658 (1994)), nucleic acid libraries (*see* Ausubel, Berger and Sambrook, all *supra*), peptide nucleic acid libraries (*see, e.g.*, U.S. Patent 5,539,083), antibody libraries (*see, e.g.*, Vaughn *et al.*, *Nature Biotechnology*, 14(3):309-314 (1996) and PCT/US96/10287), carbohydrate libraries (*see, e.g.*, Liang *et*

al., *Science*, 274:1520-1522 (1996) and U.S. Patent 5,593,853), small organic molecule libraries (*see, e.g.*, benzodiazepines, Baum C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent 5,569,588; thiazolidinones and metathiazanones, U.S. Patent 5,549,974; pyrrolidines, U.S. Patents 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent 5,506,337; benzodiazepines, 5,288,514, and the like).

Devices for the preparation of combinatorial libraries are commercially available (*see, e.g.*, 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). In addition, numerous combinatorial libraries are themselves commercially available (*see, e.g.*, ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, *etc.*).

The assays can be solid phase or solution phase assays. In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 96 modulators. If 1536 well plates are used, then a single plate can easily assay from about 100- about 1500 different compounds. It is possible to assay many plates per day; assay screens for up to about 6,000, 20,000, 50,000, or 100,000 or more different compounds is possible using the integrated systems of the invention.

DEFINITIONS

As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

"Inducing insulin gene expression" refers to increasing, in a cell or culture of cells, the level of expression from the insulin gene by at least about 25%, preferably 50%, 100%, 500%, 1000%, 5000%, or higher, as compared to a negative control culture. Insulin gene expression can be measured by methods known to those of skill in the art, *e.g.*, by measuring insulin RNA expression, preproinsulin, proinsulin, insulin, or c-peptide production, *e.g.*, using PCR, hybridization, and immunoassays.

Cells that "secrete insulin in response to glucose" are cells or a cell culture that, in comparison to a negative control (either non-insulin responsive cells or insulin

responsive cells that are not exposed to glucose), have increased insulin secretion in response to glucose of at least about 25%, preferably 50%, 100%, 500%, 1000%, 5000%, or higher than the control cells (measured as described above).

“Culturing cells” so that the cells are “in contact with other cells in the culture” refers to culture conditions that allow cell to cell contact. Under such conditions, many but not all cells are in contact with one or more other cells of the culture. Such conditions include culturing the cells on a solid surface, such as a plate or a bead, or culturing the cells in suspension.

“Endocrine pancreas cells” refers to cells originally derived from an adult or fetal pancreas, preferably islet cells. “Cultured” endocrine pancreas cells refers to primary cultures as well as cells that have been transformed with genes such as an oncogene, e.g., SV40 T antigen, ras, or a telomerase gene (e.g., hTERT).

A “GLP-1 receptor agonist” refers to GLP-1, a GLP-1 analog, or a naturally occurring peptide that binds to the GLP-1 receptor (e.g., exendin -3 or -4), thereby activating signal transduction from the receptor.

“Culturing” refers to growing cells *ex vivo* or *in vitro*. Cultured cells can be non-naturally occurring cells, e.g., cells that have been transduced with an exogenous gene such as an oncogene or a transcription factor such as PDX-1. Cultured cells can also be naturally occurring isolates or primary cultures.

A “stable” cell line or culture is one that can grow *in vitro* for an extended period of time, such as for at least about 50 cell divisions, or for about 6 months, more preferably for at least about 150 cell divisions, or at least about ten months, and more preferably at least about a year.

“Modulating β -cell function” refers to a compound that increases (activates) or decreases (inhibits) glucose responsive insulin secretion of an endocrine pancreas cell. Glucose responsive insulin secretion can be measured by a number of methods, including analysis of insulin mRNA expression, preproinsulin production, proinsulin production, insulin production, and c-peptide production, using standard methods known to of skill in the art. To examine the extent of modulation, cultured cells are treated with a potential activator or inhibitor and are compared to control samples without the activator or inhibitor. Control samples (untreated with inhibitors or activators) are assigned a relative insulin value of 100%. Inhibition is achieved when the insulin value relative to the control is about 90%, preferably 75%, 50%, and more preferably 25-0%. Activation is achieved when the insulin value relative to the control is

110%, more preferably 125%, 150%, and most preferably at least 200-500% higher or 1000% or higher.

“Transduction” refers to any method of delivering an exogenous nucleic acid, e.g., an expression vector, to a cell, including transfection, lipofection, electroporation, viral transduction, microinjection, particle bombardment, receptor mediated endocytosis,, and the like.

A diabetic subject is a mammalian subject, often a human subject, that has any type of diabetes, including primary and secondary diabetes, type 1 NIDDM-transient, type 1 IDDM, type 2 IDDM-transient, type 2 NIDDM, and type 2 MODY, as described in *Harrison's Internal Medicine*, 14th ed. 1998.

“Expressing” a gene refers to expression of a recombinant or endogenous gene, e.g., resulting in mRNA or protein production from the gene. A recombinant gene can be integrated into the genome or in an extrachromosomal element.

“Antibody” refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, for example, pepsin digests an antibody below the disulfide linkages in the hinge region to produce $F(ab)'_2$, a dimer of Fab which itself is a light chain joined to V_H - C_H1 by a disulfide bond. The $F(ab)'_2$ may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the $F(ab)'_2$ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (*see Fundamental Immunology* (Paul ed., 3d ed. 1993). While various antibody fragments are defined in

terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized *de novo* either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized *de novo* using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (*see, e.g., McCafferty et al., Nature* 348:552-554 (1990))

For preparation of monoclonal or polyclonal antibodies, any technique known in the art can be used (*see, e.g., Kohler & Milstein, Nature* 256:495-497 (1975); Kozbor *et al., Immunology Today* 4: 72 (1983); Cole *et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc. (1985)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (*see, e.g., McCafferty et al., Nature* 348:552-554 (1990); Marks *et al., Biotechnology* 10:779-783 (1992)).

The term "immunoassay" is an assay that uses an antibody to specifically bind an antigen, e.g., ELISA, western blot, RIA, immunoprecipitation and the like. The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.

"Nucleic acid" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, which have similar binding properties as the reference nucleic acid, and which are metabolized in a manner similar to the reference nucleotides. Examples of such analogs include, without limitation, phosphorothioates, phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).

Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer *et al., Nucleic Acid Res.* 19:5081 (1991);

Ohtsuka *et al.*, *J. Biol. Chem.* 260:2605-2608 (1985); Rossolini *et al.*, *Mol. Cell. Probes* 8:91-98 (1994)). The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide, and polynucleotide.

The terms "polypeptide," "peptide" and "protein" are used interchangeably
5 herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino
10 acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ -carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino
15 acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is
20 different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid.

Amino acids may be referred to herein by either their commonly known
three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB
Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by
25 their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic
acid sequences. With respect to particular nucleic acid sequences, conservatively
modified variants refers to those nucleic acids which encode identical or essentially
identical amino acid sequences, or where the nucleic acid does not encode an amino acid
30 sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide.

Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention.

The following eight groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Glycine (G);
 - 2) Aspartic acid (D), Glutamic acid (E);
 - 3) Asparagine (N), Glutamine (Q);
 - 4) Arginine (R), Lysine (K);
 - 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V);
 - 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W);
 - 7) Serine (S), Threonine (T); and
 - 8) Cysteine (C), Methionine (M)
- (see, e.g., Creighton, *Proteins* (1984)).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible"

promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence
5 directs transcription of the nucleic acid corresponding to the second sequence.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes
10 arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein indicates that the protein comprises two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

An "expression vector" is a nucleic acid construct, generated
15 recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

In one embodiment of the invention the expression vector is a viral vector,
20 preferably one that integrates into the host cell genome, such as a retroviral vector, or an adeno-associated viral vector. Examples of retroviruses, from which viral vectors of the invention can be derived, include avian retroviruses such as avian erythroblastosis virus (AMV), avian leukosis virus (ALV), avian myeloblastosis virus (ABV), avian sarcoma virus (ACV), spleen necrosis virus (SNV), and Rous sarcoma virus (RSV); non-avian
25 retroviruses such as bovine leukemia virus (BLV); feline retroviruses such as feline leukemia virus (FeLV) or feline sarcoma virus (FeSV); murine retroviruses such as murine leukemia virus (MuLV), mouse mammary tumor virus (MMTV), murine sarcoma virus (MSV), and Moloney murine sarcoma virus (MoMSV); rat sarcoma virus (RaSV); and primate retroviruses such as human T-cell lymphotropic viruses 1 and 2 (HTLV-1, 2)
30 and simian sarcoma virus (SSV). Many other suitable retroviruses are known to those of skill in the art. Often the viruses are replication deficient, i.e., capable of integration into the host genome but not capable of replication to provide infective virus.

In another embodiment of the invention, the vector is a transient vector such as an adenoviral vector, e.g., for transducing the cells with a recombinase to delete the integrated oncogenes.

5 All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily
10 apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

EXAMPLES

15 The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

20 Example I: Preparation of immortalized human pancreatic β -cell lines

To develop cell lines from human β -cells, islet preparations were enriched for β -cells based on flavin adenine dinucleotide (FAD) autofluorescence prior to retroviral infection, as described below (Fig. 1). Immunohistochemical analysis showed that cells with low FAD autofluorescence contained mostly α with a small number of β
25 cells, while cells with high FAD autofluorescence (selected cells in box) contained 96% insulin-positive cells. Glucagon but not insulin was detectable by RIA in culture medium from the low FAD population, while insulin but not glucagon was detectable in culture medium from high FAD cells.

The 96% pure insulin-positive population was used to create the β lox5 cell
30 line by infection with the LTPRRNLlox retroviral vector expressing SV40 T antigen and H-ras^{val12} (Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999)). This cell line exhibits an extended lifespan and is immortalized by infection with a retroviral vector expressing the hTERT telomerase gene (Halvorsen *et al.*, *Molecular and Cellular*

Biology 19:1864-1870 (1999)). Insulin was detectable at low levels shortly after selection in G418, but was rapidly lost (Fig. 2A, lane 9). Furthermore, *blox5* does not express other pancreatic hormones (Fig. 2C).

To isolate the cells, a single cell suspension was prepared from an adult islet preparation of 80% purity. Islets with a diameter of 50-100 μm were handpicked under direct vision using a stereoscope after staining with dethrone (60 $\mu\text{mol/L}$). Picked islets were incubated overnight in RPMI containing 2.5 mM glucose, then dissociated into single cells using non-enzymatic dissociating solution (Sigma Corp., St Louis, MO) and shaking in a 37°C water bath at 60 cycles/minute as previously described. The resulting single cell suspension was analyzed in a fluorescence-activated cell sorter (Facstar Plus, Becton Dickinson, Mansfield MA) and particle flavin adenine dinucleotide (FAD) autofluorescence (510-550 nm) was plotted against forward light scatter. Two islet cell populations became apparent when FAD autofluorescence (510-550 nm) was plotted against forward light scatter, as previously described for rat islets.

Highly autofluorescing cells were sorted into sterile Hanks BSS, washed and resuspended in RPMI containing 5 mM glucose and 10% FBS at a concentration of 2×10^6 cells/ml. Cells were aggregated into cell clusters by placing 50 μl droplets in a petri dish, gently inverting, and incubating overnight. Thereafter monolayers were initiated from the cell aggregates as previously described for adult islets on HTB-9 matrix in the presence of HGF/SF. After 2-3 days, when the cells were observed to be dividing, they were infected with high titer retroviral vector.

Example II: Growth factor expression in *blox5* cells

The expression of some of the transcription factors that are important in establishing and maintaining β -cell differentiated function was examined (Figure 3). Most significantly, PDX-1, a homeodomain transcription factor that is required for β -cell development and function, is not expressed in *blox5*, as shown by RT-PCR (not shown) or EMSA (Figure 3A, lane 2). This result differs from growth-stimulated primary cells, where PDX-1 continues to be expressed (Beattie *et al.*, *Diabetes* 48:1013-9 (1999)). BETA2, a bHLH factor important in neurogenesis as well as β -cells is not expressed in *blox5*. CREB, which plays a critical role in cAMP responsiveness in β -cells, is also not expressed (Fig. 3D). However, Pax6, which is expressed in all endocrine cells, was expressed at high levels in *blox5*, consistent with an origin from primary endocrine cells.

RIPE3b, a factor that binds to an element in the insulin promoter but that has not yet been isolated, is present as detected by EMSA (not shown). Overall, some, but not all, of the transcription factors that play important roles in establishing and maintaining β -cell function are expressed in β lox5 cells.

5

Example III: Expression of recombinant PDX-1 in β lox5 cells

Previously, it has been shown that introduction of PDX-1 into a cell line, TRM-6, derived from human fetal islets, resulted in an increase in somatostatin gene expression. PDX-1 also acted synergistically with cell-cell contact to further increase the level of somatostatin expression about 1,000-fold above the cells not expressing PDX-1, to a level similar to that found in normal human islets. To determine whether β lox5 could be induced to express pancreatic hormones, recombinant PDX-1 was expressed in β lox5 using a retroviral vector. While this resulted in functional PDX-1 expression in the cells (Fig. 3A, lane 3), in contrast to TRM-6, β lox5 did not respond to PDX-1 and cell-cell contact with an increase in hormone expression (Fig. 2A, lane 3, Fig. 2C, lane 3), despite the fact that PDX-1 expression in β lox5 resulted in functional protein as evidenced by its ability to bind DNA in EMSA (Fig. 3A, lane 3). Therefore, other factors were examined for their ability to induce hormone expression in β lox5 cells expressing PDX-1. Activin and betacellulin have been reported to be able to induce endocrine differentiation in cell lines and primary cells (Mashima *et al.*, *Diabetes* 48:304-9 (1999), Huotari *et al.*, *Endocrinology* 139, 1494-9 (1998), Mashima *et al.*, *J Clin Invest* 97:1647-54 (1996), Yamaoka *et al.*, *J Clin Invest* 102:294-301 (1998)). However, they had no effect on hormone expression in β lox5 cells (data not shown).

25 Example III: Treatment of PDX-1 expressing cells with GLP-1

GLP-1, a small peptide cleaved from the proglucagon molecule, is an insulin secretagogue (Drucker *et al.*, *Diabetes* 47:159-69 (1998)). A homolog of GLP-1 derived from Gila lizards, exendin-4, has recently been found to stimulate rodent β -cell differentiation *in vitro* and *in vivo* (Xu *et al.*, *Diabetes* 48:2270-2276 (1999), Zhou *et al.*, *Diabetes* 48:2358-66 (1999)). Therefore, exendin-4 was tested for its ability to stimulate β -cell differentiation in β lox5. 10 nmolar exendin-4 was administered to the cells for four days, and then removed from the culture medium.

By itself, exendin-4 had no effect on hormone expression in β lox5 (Fig. 2A, lane 8). However, when β lox5 cells expressing PDX-1 were grown in suspension culture as three-dimensional aggregates in the presence of the exendin-4, a substantial amount of insulin mRNA was detectable (Fig. 2A, lane 2). The nature of the interaction between exendin-4, cell-cell contact, and PDX-1 is evident from the fact that no hormone mRNA was detectable with any one or two of the three inducing factors (Fig. 2A). Quantitative RT-PCR revealed that the level of insulin mRNA in induced β lox5 cells was as that found in adult islets (Fig. 2B). Islet amyloid polypeptide (IAPP) mRNA, a hormone that is co-secreted with insulin, was also expressed in induced β lox5 cells (Fig. 2C, lane 2). However, the other major pancreatic hormones, glucagon, somatostatin, and pancreatic polypeptide (PP), were not induced (Fig. 2C).

Example IV: Expression of pancreatic hormones in PDX-1 expressing β lox5 cells

The expression of transcription factors important in β -cell development was examined to determine whether they had been induced by PDX-1, cell-cell contact, and exendin-4. BETA2 was induced only by the combination of all three inducing factors (Fig. 3C). Interestingly, CREB, which plays an important role in the cAMP response of β -cells, was induced by exendin-4 alone, independently of cell-cell contact and PDX-1 (Fig. 3D). GLP-1 has been reported to increase cAMP levels and this has been thought to be a major mechanism by which GLP-1 acts as an insulin secretagogue (Serre *et al.*, *Endocrinology* 139:4448-54 (1998)). This is the first report that activation of the GLP-1 receptor can induce CREB expression, suggesting that GLP-1 may act at multiple levels in promoting cAMP signaling. RIPE3b, a factor that plays a critical role in insulin gene expression but that has not yet been cloned, is expressed in β lox5 irrespective of PDX-1, cell-cell contact, or exendin-4 (Fig. 3E).

Example V: Glucose responsiveness

A hallmark of functional β -cells is the ability to secrete insulin in response to blood glucose. Primary β -cells store large quantities of insulin and secrete it in response to a variety of physiological stimuli, most significantly extracellular glucose. Induced β lox5 cells have an insulin content of 6 picograms per microgram DNA at 1.6 mM glucose. Intracellular insulin is easily detectable by immunohistochemistry (Fig. 4A). Media from induced β lox5 cells contains mature insulin that comigrates with bovine

insulin (Fig. 4B). A major component of the glucose-sensing apparatus is glucokinase (Matschinsky *et al.*, *Diabetes* 47:307-315 (1998)). Induced β lox5 cells express glucokinase mRNA, while uninduced cells do not (Fig. 5A). The extent to which β lox5 cells exhibit glucose-responsive insulin secretion was tested by culturing β lox5 cells in different concentrations of glucose and measuring insulin release in the culture medium by RIA (Fig. 5B). Half-maximal secretion occurred at approximately 11 mM, similar to normal adult islets.

Example VI: Transplantation of glucose responsive cells *in vivo*

10 β lox5 cells expressing PDX-1 were transfected with an adenoviral vector expressing cre, to excise the recombinant SV40 T antigen and H-ras^{val12} genes, as described in Halvorsen *et al.*, *Molecular and Cellular Biology* 19:1864-1870 (1999). The cells had been previously stimulated with exendin-4, as described above. The cells were transplanted under the kidney capsule of nude mice for three months. One to ten million
15 cells were transplanted in a mice that weighed about 25 grams. After three months, the mice were bled for c-peptide and the grafts were harvested. C-peptide was measured according to standard procedures using RIA (Fig. 6). These cells exhibit glucose-responsive insulin secretion.

WHAT IS CLAIMED IS:

- 1 1. A method for inducing insulin gene expression in cultured
2 endocrine pancreas cells, the method comprising the steps of:
3 (i) expressing a PDX-1 gene in cells that have been cultured under
4 conditions such that the cells are in contact with other cells in the culture; and
5 (ii) contacting the cells with a GLP-1 receptor agonist, thereby inducing
6 insulin gene expression in the cells.
- 1 2. The method of claim 1, wherein the GLP-1 receptor agonist is a
2 GLP-1 analog.
- 1 3. The method of claim 1, wherein the GLP-1 receptor agonist has an
2 amino acid sequence of a naturally occurring peptide.
- 1 4. The method of claim 3, wherein the GLP-1 receptor agonist is
2 GLP-1, exendin-3, or exendin-4.
- 1 5. The method of claim 1, wherein the cells are cultured as aggregates
2 in suspension.
- 1 6. The method of claim 1, wherein the PDX-1 gene is endogenous to
2 the cells.
- 1 7. The method of claim 1, wherein the PDX-1 gene is recombinant.
- 1 8. The method of claim 1, wherein the cells are human cells.
- 1 9. The method of claim 1, wherein the cells express a recombinant
2 oncogene.
- 1 10. The method of claim 9, wherein the cells express more than one
2 recombinant oncogene.
- 1 11. The method of claim 1, wherein the cells express a recombinant
2 telomerase gene.
- 1 12. The method of claim 1, wherein the cells are β lox5 cells.

1 13. A method of identifying a compound that modulates β -cell
2 function, the method comprising the steps of contacting cells made by the method of
3 claim 1 with the compound and determining the effect of the compound on β -cell
4 function.

1 14. A method for inducing insulin gene expression in cultured pancreas
2 cells, the method comprising contacting a culture of endocrine pancreas cells expressing a
3 PDX-1 gene with a GLP-1 receptor agonist, wherein said cells have been cultured under
4 conditions such that the cells are in contact with other cells in the culture, thereby
5 inducing insulin gene expression in the cells.

1 15. A stable culture of endocrine pancreas cells, wherein the cells are
2 in contact with other cells in the culture, wherein the cells express a PDX-1 gene, and
3 wherein insulin gene expression is stimulated in the cells when exposed to an effective
4 amount of a GLP-1 receptor agonist.

1 16. The culture of claim 15, wherein the GLP-1 receptor agonist is a
2 GLP-1 analog.

1 17. The culture of claim 15, wherein the GLP-1 receptor agonist has an
2 amino acid sequence of a naturally occurring peptide.

1 18. The culture of claim 17, wherein the GLP-1 receptor agonist is
2 GLP-1, exendin-3, or exendin-4.

1 19. The culture of claim 15, wherein the cells are cultured as
2 aggregates in suspension.

1 20. The culture of claim 15, wherein the PDX-1 gene is endogenous to
2 the cells.

1 21. The culture of claim 15, wherein the PDX-1 gene is recombinant.

1 22. The culture of claim 15, wherein the cells are human cells.

1 23. The culture of claim 15, wherein the cells express a recombinant
2 oncogene.

1 24. The culture of claim 23, wherein the cells express more than one
2 recombinant oncogene.

1 25. The culture of claim 15, wherein the cells express a recombinant
2 telomerase gene.

1 26. The culture of claim 15, wherein the cells are β lox5 cells.

1 27. A method of identifying a compound that modulates β -cell
2 function, the method comprising the steps of contacting the culture of claim 15 with the
3 compound and determining the effect of the compound on β -cell function.

1 28. A method of treating a diabetic subject by providing to the subject
2 cells that secrete insulin in response to glucose, the method comprising the step of
3 administering to the subject an effective amount of cells according to claim 1.

1 29. A method of treating a diabetic subject by providing to the subject
2 cells that secrete insulin in response to glucose, the method comprising the steps of:
3 (i) contacting a culture of endocrine pancreas cells expressing a PDX gene
4 with a GLP-1 receptor agonist, wherein the cells have been cultured under conditions
5 such that the cells are in contact with other cells in the culture; and
6 (ii) administering the cells to the subject, thereby providing to the subject
7 cells that secrete insulin in response to glucose.

1 30. The method of claim 29, wherein the diabetic subject is a human.

1 31. The method of claim 30, wherein the subject has Type I insulin
2 dependent diabetes.

1 32. The method of claim 29, wherein the GLP-1 receptor agonist is a
2 GLP-1 analog.

1 33. The method of claim 29, wherein the GLP-1 receptor agonist has
2 an amino acid sequence of a naturally occurring peptide.

1 34. The method of claim 33, wherein the GLP-1 receptor agonist is
2 GLP-1, exendin-3, or exendin-4.

- 1 35. The method of claim 29, wherein the cells are cultured as
2 aggregates in suspension.
- 1 36. The method of claim 29, wherein the PDX-1 gene is endogenous to
2 the cells.
- 1 37. The method of claim 29, wherein the PDX-1 gene is recombinant.

1/5




FIG. 1.




FIG. 2A.




FIG. 2B.




FIG. 2C.

2/5



FIG. 3A.




FIG. 3B.




FIG. 3C.




FIG. 3D.







FIG. 3E.

3/5

*FIG. 4A.**FIG. 4B.**FIG. 4C.**FIG. 4D.*

4/5

**FIG. 5A.****FIG. 5B.**

5/5




FIG. 6.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/07628

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 35/12, 38/28; C12Q 1/00; C12N 5/08, 5/10
 US CL : 530/303; 424/93.2, 93.7; 435/4, 70.1, 366, 375, 455

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 530/303; 424/93.2, 93.7; 435/4, 70.1, 366, 375, 455

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 5,424,286 A (ENG) 13 June 1995 (13.06.1995), see whole document, especially columns 5 and 8.	1,3,4,6,9,13-18,20,23 ----- 2,5,7,8,10,11,19,21,2 2,24,25
X --- Y	US 5,614,492 A (HABENER) 25 March 1997 (25.03.1997), see whole document, especially columns 7, 8, 11, 12, 13, 15, and 29.	1,3,4,6,9,13-18,20,23 ----- 2,5,7,8,10,11,19,21,2 2,24,25
Y	US 5,888,816 A (COON et al.) 30 March 1999 (30.03.1999), see whole document, especially column 22.	8,22
Y	WO 97/16536 A (SOON-SHIONG et al.) 09 May 1997 (09.05.1997), see whole document, especially pages 5-7 and 40-41.	5,19,8,22
Y	US 5,981,488 A (HOFFMANN) 09 November 1999 (09.11.1999), see whole document, especially column 3.	2, 16
Y	US 5,545,618 A (BUCKLEY et al.) 13 August 1996 (13.08.1996), see whole document.	2, 16
Y	US 5,858 973 A (HABENER et al.) 12 January 1999 (12.01.1999), see whole document, especially column 19.	7,21



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier application or patent published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

14 May 2001 (14.05.2001)

Date of mailing of the international search report

25 JUN 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Lisa Gansheroff

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/07628

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 6,087,129 A (NEWGARD et al.) 11 July 2000 (11.07.2000), see whole document, especially columns 59, 78-79.	7, 21
Y	HALVORSEN et al. Telomerase activity is sufficient to allow transformed cells to escape from crisis. Molecular and Cellular Biology. March 1999, Vol. 19, pages 1864-1870, see whole document.	10, 11, 24, 25
A	D'AMBRA et al. Regulation of insulin secretion from Beta-cell lines derived from transgenic mice insulinomas resembles that of normal Beta-cells. Endocrinology. 1990, Vol. 126, pages 2815-2822.	1-37.
A	SHARMA et al. Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. Molecular and Cellular Biology. 1997. Vol. 17, pages 2598-2604.	1-37

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/07628

Continuation of B. FIELDS SEARCHED Item 3: WEST (USPT, JPAB, EPAB, DWPI) and STN (Medline, Biosis, Caplus)

search terms: insulin, islet, beta, diabetes, pancreas, identify, compound, agonist, screen, exendin, glp-1, glucagon like peptide, graft, engraft, transplant, implant, pdx-1, stf-1, idx-1, ipf-1, recombinant, tranfect, vector, plasmid, genetic engineer, Levine F, Dufayet D